Publications:

---

Current therapy and development of therapeutic agents for lung cancer.

Cell Insight

Wang, Zilai Z; Kim, Jiyeon J; Zhang, Pin P; Galvan Achi, Jazmin M JM; Jiang, Yuwei Y; Rong, Lijun L

Publication Date: 2022-04

Variant appearance in text: EGFR: L692V

PubMed Link: 37193130

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling.

Frontiers In Oncology

Hintzen, Gabriele G; Dulat, Holger J HJ; Rajkovic, Erich E

Publication Date: 2022

Variant appearance in text: EGFR: L692V

PubMed Link: 36185288

Variant Present in the following documents:

• Main text
• fonc-12-892212.pdf

View BVdb publication page

---

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.

Signal Transduction And Targeted Therapy

Yang, Yang Y; Li, Shuo S; Wang, Yujiao Y; Zhao, Yi Y; Li, Qiu Q

Publication Date: 2022-09-17

Variant appearance in text: EGFR: L692V

PubMed Link: 36115852

Variant Present in the following documents:

• Main text

View BVdb publication page

---

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.

Nature Communications

Niu, Mengmeng M; Xu, Jing J; Liu, Yang Y; Li, Yuhuang Y; He, Tao T; Ding, Liangping L; He, Yajun Y; Yi, Yong Y; Li, Fengtian F; Guo, Rongtian R; Gao, Ya Y; Li, Rui R; Li, Luping L; Fu, Mengyuan M; Hu, Qingyong Q; Luo, Yangkun Y; Zhang, Chunyan C; Qin, Kewei K; Yi, Jianqiao J; Yu, Shuhan S; Yang, Jian J; Chen, Hu H; Wang, Liang L; Li, Zhonghan Z; Dong, Biao B; Qi, Shiqian S; Ouyang, Liang L; Zhang, Yujun Y; Cao, Yang Y; Xiao, Zhi-Xiong Jim ZJ

Publication Date: 2021-10-11

Variant appearance in text: EGFR: L692V

PubMed Link: 34635651

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).

International Journal Of Oncology

He, Jingyi J; Huang, Zhengrong Z; Han, Linzhi L; Gong, Yan Y; Xie, Conghua C

Publication Date: 2021-11

Variant appearance in text: EGFR: L692V

PubMed Link: 34558640

Variant Present in the following documents:

• Main text
• ijo-59-05-05270.pdf

View BVdb publication page

---

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer.

Cancers

Wang, Tong-Hong TH; Wu, Chih-Ching CC; Huang, Kuo-Yen KY; Leu, Yann-Lii YL; Yang, Shuenn-Chen SC; Chen, Ci-Ling CL; Chen, Chi-Yuan CY

Publication Date: 2020-12-31

Variant appearance in text: EGFR: L692V

PubMed Link: 33396393

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.

Frontiers In Oncology

Wu, Leilei L; Ke, Linping L; Zhang, Zhenshan Z; Yu, Jinming J; Meng, Xue X

Publication Date: 2020

Variant appearance in text: EGFR: L692V

PubMed Link: 33392095

Variant Present in the following documents:

• Main text
• fonc-10-602762.pdf

View BVdb publication page

---

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).

Pharmaceuticals (Basel, Switzerland)

O'Leary, Connor C; Gasper, Harry H; Sahin, Katherine B KB; Tang, Ming M; Kulasinghe, Arutha A; Adams, Mark N MN; Richard, Derek J DJ; O'Byrne, Ken J KJ

Publication Date: 2020-09-25

Variant appearance in text: EGFR: L692V

PubMed Link: 32992872

Variant Present in the following documents:

• Main text
• pharmaceuticals-13-00273.pdf

View BVdb publication page

---

[Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi = Chinese Journal Of Lung Cancer

Zhao, Zitong Z; Ni, Yu Y; Li, Li L; Xin, Tao T

Publication Date: 2020-04-20

Variant appearance in text: EGFR: L692V

PubMed Link: 32316715

Variant Present in the following documents:

• zgfazz-23-4-274.pdf

View BVdb publication page

---

Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.

Esmo Open

Berghoff, Anna S AS; Bellosillo, Beatriz B; Caux, Christophe C; de Langen, Adrianus A; Mazieres, Julien J; Normanno, Nicola N; Preusser, Matthias M; Provencio, Mariano M; Rojo, Federico F; Wolf, Jurgen J; Zielinski, Christoph C CC

Publication Date: 2019

Variant appearance in text: EGFR: L692V

PubMed Link: 31297240

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

Cancers

Le, Tri T; Gerber, David E DE

Publication Date: 2019-03-15

Variant appearance in text: EGFR: L692V

PubMed Link: 30875928

Variant Present in the following documents:

• Main text
• cancers-11-00366.pdf

View BVdb publication page

---

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?

Journal Of Clinical Medicine

Garinet, Simon S; Laurent-Puig, Pierre P; Blons, Hélène H; Oudart, Jean-Baptiste JB

Publication Date: 2018-06-09

Variant appearance in text: EGFR: Leu692Val

PubMed Link: 29890761

Variant Present in the following documents:

• Main text
• jcm-07-00144.pdf

View BVdb publication page

---

[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi = Chinese Journal Of Lung Cancer

Ni, Lianfang L; Nie, Ligong L

Publication Date: 2018-02-20

Variant appearance in text: EGFR: L692V

PubMed Link: 29526178

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.

Cancers

Hofman, Paul P

Publication Date: 2017-11-10

Variant appearance in text: EGFR: L692V

PubMed Link: 29125548

Variant Present in the following documents:

• Main text
• cancers-09-00154.pdf

View BVdb publication page

---

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.

Frontiers In Oncology

Barnes, Tristan A TA; O'Kane, Grainne M GM; Vincent, Mark David MD; Leighl, Natasha B NB

Publication Date: 2017

Variant appearance in text: EGFR: L692V

PubMed Link: 28620581

Variant Present in the following documents:

• Main text
• fonc-07-00113.pdf

View BVdb publication page

---

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

Translational Lung Cancer Research

Minari, Roberta R; Bordi, Paola P; Tiseo, Marcello M

Publication Date: 2016-12

Variant appearance in text: EGFR: L692V

PubMed Link: 28149764

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Nature Communications

Chabon, Jacob J JJ; Simmons, Andrew D AD; Lovejoy, Alexander F AF; Esfahani, Mohammad S MS; Newman, Aaron M AM; Haringsma, Henry J HJ; Kurtz, David M DM; Stehr, Henning H; Scherer, Florian F; Karlovich, Chris A CA; Harding, Thomas C TC; Durkin, Kathleen A KA; Otterson, Gregory A GA; Purcell, W Thomas WT; Camidge, D Ross DR; Goldman, Jonathan W JW; Sequist, Lecia V LV; Piotrowska, Zofia Z; Wakelee, Heather A HA; Neal, Joel W JW; Alizadeh, Ash A AA; Diehn, Maximilian M

Publication Date: 2016-06-10

Variant appearance in text: EGFR: L692V

PubMed Link: 27283993

Variant Present in the following documents:

• Main text
• ncomms11815-s2.xlsx, sheet 1
• ncomms11815-s1.pdf
• ncomms11815.pdf

View BVdb publication page

---

EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis.

Scientific Reports

Cheng, Chao C; Wang, Rui R; Li, Yuan Y; Pan, Yunjian Y; Zhang, Yang Y; Li, Hang H; Zheng, Difan D; Zheng, Shanbo S; Shen, Xuxia X; Sun, Yihua Y; Chen, Haiquan H

Publication Date: 2015-09-10

Variant appearance in text: EGFR: L692V

PubMed Link: 26354324

Variant Present in the following documents:

• Main text
• srep13959.pdf

View BVdb publication page

---

Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

Zhang, Yang Y; Sun, Yihua Y; Pan, Yunjian Y; Li, Chenguang C; Shen, Lei L; Li, Yuan Y; Luo, Xiaoyang X; Ye, Ting T; Wang, Rui R; Hu, Haichuan H; Li, Hang H; Wang, Lei L; Pao, William W; Chen, Haiquan H

Publication Date: 2012-04-01

Variant appearance in text: EGFR: L692V

PubMed Link: 22317764

Variant Present in the following documents:

• Main text

View BVdb publication page

---